Comparative Pharmacology
Head-to-head clinical analysis: FOCINVEZ versus MONISTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOCINVEZ versus MONISTAT.
FOCINVEZ vs MONISTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FOCINVEZ is a small-molecule inhibitor of the interaction between the N-terminal domain of the androgen receptor (AR) and the AR N-terminal domain coactivator binding site, thereby blocking AR-mediated gene transcription and inhibiting prostate cancer cell growth.
Miconazole, the active ingredient in MONISTAT, inhibits fungal CYP51 (lanosterol 14-alpha-demethylase), blocking ergosterol synthesis and disrupting fungal cell membrane integrity, leading to cell death.
Intravenous: 1.5 mg/kg every 6 hours; maximum single dose: 200 mg.
Intravaginal: 200 mg suppository at bedtime for 3 days, or 100 mg suppository at bedtime for 7 days, or 2% cream 5 g intravaginally at bedtime for 7 days. Topical: Apply 2% cream twice daily for 2-4 weeks.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; allows twice-daily dosing in most patients, extended in renal impairment (up to 30-40 hours in severe impairment).
Approximately 90-120 minutes; supports twice-daily local dosing.
Renal: 70% (unchanged drug), Biliary/Fecal: 20% (metabolites), Other: 10% (minor pathways).
Primarily fecal (approximately 90%) as unchanged drug; less than 2% renal elimination.
Category C
Category C
Antifungal
Antifungal